$74.55
0.53[0.72%]
At close: Apr 26
$74.55
0[0.00%]
After Hours: 4:16PM EDT
Dr Reddy's Laboratories
(NYSE:RDY)Latest News for Dr Reddy's Laboratories Stock (NYSE:RDY)
Dr Reddy's Laboratories Stock (NYSE: RDY)
Categories: All
Thursday, April 25, 2024
- Dr. Reddy's Laboratories shares are trading higher. The company and Nestle India entered into a definitive agreement to form a join venture to take health science nutraceutical brands to consumers in India and other agreed territories.Benzinga Newsdesk - 2 days ago
- Nestlé India And Dr. Reddy's To Form Joint Venture To Take Health Science Nutraceutical Portfolio To Consumers Across India And Other Agreed TerritoriesBenzinga Newsdesk - 3 days ago
Wednesday, April 10, 2024
Wednesday, March 27, 2024
Thursday, February 22, 2024
Wednesday, January 31, 2024
Tuesday, January 30, 2024
Monday, January 29, 2024
Wednesday, January 03, 2024
Thursday, December 14, 2023
Monday, December 11, 2023
Wednesday, December 06, 2023
- Dr. Reddy's To Make $7.5M Upfront Payment To Coya, $4.2M Payment Upon Acceptance Of IND Application, $4.2M Upon First Patient Dosing In Phase 2 Trial And Development And Regulatory Milestones Of Up To $40M; Coya Is Eligible For Up To $677.25M In Sales-Based MilestonesBenzinga Newsdesk - Dec 6, 2023, 7:09AM
- Coya Therapeutics And Dr. Reddy's Laboratories Enter Exclusive Collaboration For Development And Commercialization Of COYA 302 For ALS, Under Which Dr. Reddy's Will Obtain Commercialization Rights For COYA 302 In US, Canada, UK And EUBenzinga Newsdesk - Dec 6, 2023, 7:05AM
Thursday, November 16, 2023
Wednesday, August 23, 2023
Wednesday, July 26, 2023
Wednesday, July 12, 2023
Tuesday, July 11, 2023
Tuesday, June 13, 2023
Thursday, June 01, 2023
Tuesday, May 16, 2023
Wednesday, May 10, 2023
Friday, April 21, 2023
Thursday, April 20, 2023
- Why Aditxt Shares Are Surging TodayNabaparna Bhattacharya - Apr 20, 2023, 2:20PM
- Aditxt Signs Asset Purchase Agreement To Acquire 50% Ownership Of Global Response Aid With Rights To Manufacture And Market Broad-Spectrum Antiviral Drug Avigan; The Consideration For The Transaction Is $24.5MHappy Mohamed - Apr 20, 2023, 8:17AM
Wednesday, April 05, 2023
Wednesday, March 22, 2023
Monday, March 20, 2023
- Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302Kenneth Adams - Sponsored
- Coya Therapeutics Announced A Worldwide Agreement With Dr. Reddy's Laboratories To In-license Proposed Abatacept Biosimilar Of Dr. Reddy's To Develop Coya's Combination Product For Neurodegenerative Diseases, COYA 302, Deal Terms Not DisclosedBenzinga Newsdesk - Mar 20, 2023, 7:06AM
Monday, February 27, 2023
- Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription DealVandana Singh - Feb 27, 2023, 1:04PM
- Dr. Reddy's Laboratories Announced Late Sunday Agreement To Acquire Mayne Pharma's U.S. Generic Prescription Product PortfolioCharles Gross - Feb 27, 2023, 5:27AM